FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Venrock Associates VI, L.P.
2. Issuer Name and Ticker or Trading Symbol

10x Genomics, Inc. [ TXG ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    __X__ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

C/O VENROCK, 3340 HILLVIEW AVENUE
3. Date of Earliest Transaction (MM/DD/YYYY)

9/16/2020
(Street)

PALO ALTO, CA 94304
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 9/16/2020  J(1)  911981 (1)D$0.00 375844 I By Funds (2)
Class A Common Stock 9/18/2020  J(3)  338019 (3)D$0.00 37825 I By Funds (4)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares

Explanation of Responses:
(1) On September 16, 2020, Venrock Associates VI, L.P. ("VA VI") and Venrock Partners VI, L.P. ("VP VI") distributed an aggregate of 1,250,000 shares of Class A Common Stock to their limited partners and general partners pursuant to a Trading and Distribution Plan adopted on September 11, 2020 (the "Plan"). Pursuant to the terms of the Plan, of the 1,250,000 shares distributed, 313,898 shares were distributed by VA VI to its general partner, Venrock Management VI, LLC ("VM VI") and 24,121 shares were distributed by VP VI to its general partner, Venrock Partners Management VI, LLC ("VPM VI").
(2) Consists of 35,085 shares of Class A Common Stock held by VA VI, 2,740 shares of Class A Common Stock held by VP VI, 313,898 shares of Class A Common Stock held by VM VI and 24,121 shares of Class A Common Stock held by VPM VI.
(3) On September 18, 2020, VM VI and VPM VI distributed an aggregate of 338,019 shares of Class A Common Stock to their members and participants pursuant to the Plan.
(4) Consists of 35,085 shares of Class A Common Stock held by VA VI and 2,740 shares of Class A Common Stock held by VP VI.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Venrock Associates VI, L.P.
C/O VENROCK
3340 HILLVIEW AVENUE
PALO ALTO, CA 94304

X

Venrock Partners VI, L.P.
C/O VENROCK, 3340 HILLVIEW AVENUE
PALO ALTO, CA 94304

X

Venrock Management VI, LLC
C/O VENROCK, 3340 HILLVIEW AVENUE
PALO ALTO, CA 94304

X

Venrock Partners Management VI, LLC
C/O VENROCK, 3340 HILLVIEW AVENUE
PALO ALTO, CA 94304

X


Signatures
/s/ David L. Stepp, Authorized Signatory9/18/2020
**Signature of Reporting PersonDate

David L. Stepp, Authorized Signatory9/18/2020
**Signature of Reporting PersonDate

David L. Stepp, Authorized Signatory9/18/2020
**Signature of Reporting PersonDate

David L. Stepp, Authorized Signatory9/18/2020
**Signature of Reporting PersonDate

10x Genomics (NASDAQ:TXG)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more 10x Genomics Charts.
10x Genomics (NASDAQ:TXG)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more 10x Genomics Charts.